5Palmer AJ,Roze S,Valentine WJ,et al.The CORE Diabetes Model:projecting long-term clinical outcomes,costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.Curr Med Res Opin,2004,20(suppl 1):S5-S26.
6Valentine WJ,Goodall G.Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany:a modelling study of long-term clinical and cost outcomes.AdvTher,2008,25:567-584.
7Valentine WJ,Erny-Albrecht KM.Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents:a modeling study of cost-effectiveness in the United States.Advance in Therapy,2007,24:273-290.
8Yang L,Christensen T,White J,et al.Pharmacoeconomic evaluation of detemir versus glargine for the treatment of type 2 diabetes in China.ISPOR 15th Annual International Meeting,2010.
9Palmer AJ,Valentine WJ,Ray JA,et al.An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.Current Medical Research and Opinion,2007,23:895-901.
10Tunis SL,Minshall ME,Conner,et al.Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting:modeling analysis.Current Medical Research and Opinion,2009,25:1273-1284.
二级参考文献2
1A. M. Hennige,T. Sartorius,O. Tschritter,H. Preissl,A. Fritsche,P. Ruth,H.-U. H?ring. Tissue selectivity of insulin detemir action in vivo[J] 2006,Diabetologia(6):1274～1282
2S. V. M. Hordern,J. E. Wright,A. M. Umpleby,F. Shojaee-Moradie,J. Amiss,D. L. Russell-Jones. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp[J] 2005,Diabetologia(3):420～426
